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ABSTRACT 
The Chem2Bio2RDF portal is a Linked Open Data (LOD) portal 
for systems chemical biology aiming for facilitating drug 
discovery. It converts around 25 different datasets on genes, 
compounds, drugs, pathways, side effects, diseases, and 
MEDLINE/PubMed documents into RDF triples and links them 
to other LOD bubbles, such as Bio2RDF, LODD and DBPedia. 
The portal is based on D2R server and provides a SPARQL 
endpoint, but adds on few unique features like RDF faceted 
browser, user-friendly SPARQL query generator, 
MEDLINE/PubMed cross validation service,  and Cytoscape 
visualization plugin. Three use cases demonstrate the 
functionality and usability of this portal.  
Categories and Subject Descriptors 
D.2.12 [Interoperability]: Data Mapping 
General Terms 
Experimentation 
Keywords 
Semantic Web, RDF, SPARQL, Systems Chemical Biology 
1. INTRODUCTION 
Curing disease and providing better health care require a synthesis 
of data and understanding across different disciplines, domains, 
and applications. The information and data are most useful when 
they are well integrated with each other. Traditional data 
integration techniques relying on static mapping methodologies 
are unlikely to be scalable. Recent advances in biology and 
medicine have led to an explosion of new data sources, such as 
genes, proteins, genetic variations, chemical compounds, diseases 
and drugs. Since these data are disconnected, it is very 
challenging for biomedical scientists to identify related genes 
through different diseases, to discovery new drugs, and to 
interconnect compounds with pathways. The recent development 
of chemical and biological sciences has resulted in the emergence 
of fields like systems biology which adopt a comprehensive 
approach to the study of biological systems, chemogenomics, and 
systems chemical biology [20].  
Systems chemical biology is a new and developing area, with 
current application in polypharmacology [5, 12] and adverse drug 
reaction [22] addressing problems in efficacy and toxicity, which 
are the two main reasons accounting for the drug failure in the 
drug discovery. Polypharmacology and adverse drug reaction 
involve linking heterogeneous chemical and biological data with 
broad range of scales from small molecules (small compound, 
drug), to super-molecules (gene, protein), to biological systems 
(protein complex, pathway), and to phenotypes (disease, side 
effects). In addition, many databases cover similar data (called 
homogeneous data here) but with slightly different focuses. For 
instance, DrugBank 1  has drug target association, while 
PharmGKB2 has similar information from different perspectives. 
All the heterogeneous and homogeneous data are scattered around 
the web and published in diverse formats (i.e., text file, XML and 
relational database). Data integration is essential to systems 
chemical biology. 
Semantic Web technologies enable data integration and data 
interlinking on the Web and demonstrate promising potentials in 
life sciences, healthcare and drug discovery [17, 19, 23]. 
Integrating heterogeneous data is obviously necessary for 
advanced network biology and network medicine research [6]. 
Bio2RDF [3] manages to integrate public bioinformatics 
databases and convert them into 46 million RDF triples. Linking 
Open Drug Data (LODD) [13] links various sources of drug data 
together to answer interesting scientific and business questions.     
Bio2RDF already covers most of biological data (e.g., protein and 
pathway) and LODD has collected various sources relating to 
chemicals (particularly drugs), although some efforts have been 
made to link both together [7], its practical application is still not 
fully explored. The integration of chemical and biology data is 
actually an interaction between small compounds and proteins, 
usually called chemogenomics data. However, little effort has 
been allocated currently to integrate them. In this paper, we build 
the system called Chem2Bio2RDF to address these issues around 
system chemical biology [28]. 
    The contribution of this paper can be summarized as follows: 
 We have aggregated and converted a variety of public 
chemogenomics data distributed around the Web into RDF 
formats, which enables linking with other biological 
Semantic Web information resources such as Bio2RDF and 
LODD.  
 We built up a portal called Chem2Bio2RDF and designed a 
faceted browser to display DrugBank data, which can be 
further extended to other LOD bubbles.  
 We prototyped an automatic SPARQL query generator so 
that user can avoid writing complicated SPARQL queries. 
 We provided a MEDLINE/PubMed literature cross-
validation service so that the SPARQL query results can be 
cross-validated by related literatures in MEDLINE/PubMed.  
 We prototype a Cytoscape plugin for this portal. 
    This paper is organized as the following: Section 2 surveys the 
related works; Section 3 describes the Chem2BIO2RDF portal 
and its unique features; Section 4 discusses three cases to prove 
the concept and Section 5 evaluates the methods; Section 6makes 
the conclusion and points out future research. 
                                                                 
1 http://drugbank.ca/ 
2 http://www.pharmgkb.org/ 
2.  Related works  
In 2009, there are around 1,170 molecular biology databases 
reported by Nucleic Acids Research (NAR). This huge amount of 
databases creates data deluge that bioinformaticians have huge 
difficulty to deal with. Most of the data only begins to make sense 
when it is integrated with others. W3C formed the Health Care 
and Life Sciences (HCLS) Interest Group to develop, advocate 
for, and support the user of Semantic Web technologies for 
biological science, translational medicine and health care. Its 
recent effort on linking open drug data (LODD) LODD linked 
RDF data from the Linked Clinical Trials dataset derived from 
ClinicialTriasl.gov, DrugBank (a repository of almost 5000 FDA-
approved drugs), DailyMed published by the National Library of 
Medicine, SIDER containing information on marketed drugs and 
their recorded adverse reactions, TCMGeneDIT about Traditional 
Chinese Medicine, Diseasome with 4,300 disorders and genes 
from Online Mendelian Inheritance in Man (OMIM). Overall, 
there are more than 8.4 million RDF triples and 388,000 links to 
external data sources [13]. 
    Bio2RDF [3] is a system based on RDFizer, the Sesame open 
source triple store and an OWL ontology. It converts KEGG, 
PDB, MGI, HGNC and several NCBI databases into RDF triples. 
It successfully applied the Semantic Web technology to convert 
public biomedical data into a knowledge space of RDF documents 
based on a shared common ontology. It demos the potential to 
explore the implication of four transcription factor genes in 
Pakinson’s disease. Similar earlier efforts are YeastHub [8], 
LinkHub [25], BioDash [18] and BioGateway [2]. 
    Villanueva-Rosales, Osbahr and Dumontier (2007) [25] 
extended the Open Biomedical Ontologies (OBO) to represent 
knowledge in the Saccharomyces Genomes Database so that 
semantically sophisticated queries can be answered by a reasoner. 
The authors also identified significant challenges towards such 
directions, such as the automated creation and population of 
ontologies, the efficient storage of ontological data for reasoning 
and the development of intuitive interfaces for others.  
    Cheung, et al [7] created two health care and life science 
semantic knowledge bases and used Semantic Web technologies 
to represent, map and dynamically query multiple datasets. They 
developed a prototype receptor explorer using OWL mappings to 
provide an integrated list of receptors and executing individual 
queries against different SPARQL endpoints. Their toolset called 
“FeDeRate” enables a global SPARQL query to be decomposed 
into subqueries against the remote databases offering either 
SPARQL or SQL query interfaces. 
    Flexible and efficient data integration is highly desired in life 
sciences. In summary, there are two major kinds of efforts: 
integrating different databases by using bridge tables or splitting 
queries into sub-queries to federate results. The first effort is not 
scalable once more tables need to be integrated as data flow 
programs need to be recoded. The second effort faces the major 
issue of query efficiency and query repackaging [7]. Semantic 
web approaches convert the current life science databases into a 
global database with unique and dereferencable URIs, machine-
processable semantics, and reasoning and pattern-matching based 
SPARQL queries. A dereferenceable URI helps to not only 
uniquely identify information but also locate information. This 
allows anyone to create new RDF graphs by interlinking different 
existing RDF graphs.  
3. Chem2Bio2RDF portal  
3.1 Datasets  
 
Figure 1. Overview of the Chem2Bio2RDF Datasets 
The current Chem2Bio2RDF portal covers 25 datasets relating to 
systems chemical biology, which is grouped into 6 domains, 
namely chemical (PubChem Compound, ChEBI, PDB Ligand), 
chemogenomics (KEGG Ligand, CTD Chemical, BindingDB, 
MATADOR, PubChem BioAssay, QSAR, TTD, DrugBank, 
ChEMBL, Binding MOAD, PDSP, PharmGKB), biological 
(UNIPROT, HGNC, PDB, GI), systems (KEGG Pathway, 
Reactome, PPI, DIP), phenotype (OMIM, Diseasome, SIDER, 
CTD diseases) and literature (MEDLINE/PubMed).  Some of data 
sources cross multiple domains. As the time of writing, the 
numbers of triples is about 78 million (Figure 1).  
    As the RDF presentations of the dataset in other domains have 
been reported (i.e., LODD, Bio2RDF), our focus is on the 
chemogenomics data highlighted in figure 1. Some of the major 
datasets we integrated are: 
 PubChem BioAssay [29]: PubChem is a public repository of 
chemical information including structures of small molecules 
and various molecular properties. It has three databases 
namely Compound, Substance and BioAssay. The BioAssay 
database contains experimental results of the compounds in 
PubChem that have been tested in MLI screening centers or 
elsewhere against particular biological targets. We only 
selected the enzymatic assays that study one target and its 
associated active compounds. 
 KEGG [30]: A collection of online databases curate 
chemical, genome and pathway information. One of its 
databases KEGG Ligand has the biological molecules 
associated with its enzymes.  
 CTD [31]: Comparative Toxicogenomics Database (CTD) 
focuses on the effects of environmental chemicals on human 
disease.  
 BindingDB [32]: It provides binding affinities on the 
interactions of protein with small, drug-like molecules. The 
data are extracted from the scientific literature, focusing on 
the proteins that are drug-targets or candidate drug-targets.  
 Matador [33]: Compared to DrugBank, MATADOR 
(Manually Annotated Targets and Drugs Online Resource) 
provides the indirect interaction between chemicals and 
targets that is collected by automated text-mining followed 
by manual curation.  
 QSAR: We manually collected a set of small QSAR datasets 
from two websites (http://www.cheminformatics.org/,  
http://www.qsarworld.com/qsar-datasets.php), which aim to 
accumulate all the QSAR dataset published along with the 
paper. Only the dataset with a particular target was selected.  
 TTD [34]: Therapeutic Target Database (TTD) provides 
information about the known therapeutic proteins and 
nucleic acids described in the literature and their 
corresponding drugs/ligands.   
 DrugBank [35]: It combines detailed drug (i.e. chemical, 
pharmacological and pharmaceutical) data with 
comprehensive drug target (i.e. sequence, structure, and 
pathway) information. The database contains nearly 4,800 
drug entries and more than 2,500 non-redundant protein. 
 ChEMBL [36]: ChEMBL focuses on the interactions and 
functional effects of small molecules binding to their 
macromolecular targets. It provides 500,000 bioactive 
compounds, their quantitative properties and bioactivities 
(binding constants, pharmacology and ADMET, etc). 
 PDSP [37]: PDSP Ki database provides information on the 
abilities of drugs to interact with an expanding number of 
molecular targets. It provides Ki value (one measure of 
binding affinity) for its 766,000 interaction.  
 PharmGKB [38]: It curates primary genotype and phenotype 
data, annotate gene variants and gene-drug-disease 
relationships via literature review. 
 Binding MOAD [39]: Mother Of ALL Databases (MOAD) 
collects all well resolved protein crystal structures with 
clearly identified biologically relevant ligands annotated 
with experimentally determined binding data extracted from 
literature. All the structures are extracted from Protein Data 
Bank (PDB), containing very high-quality ligand-protein 
binding. 
    The detailed data processing was reported in our previous work 
[28]. We add simple provenance (What, When, Where, Why, and 
Who) to the RDF resources, which can be viewed at our website 
(chem2bio2rdf.org/datasets.html). The user can explore the RDF 
resources using the filter function. For example, the Figure 2 
shows all the chemogenomics RDF resources which are extracted 
from literature.  
 
Figure 2. Faceted Browser for the datasets 
All the data was processed from its original dataset, however, 
some of them does not meet the further utilization. For example,  
BindingDB uses string (i.e., >0.5) instead of number to present its 
binding affinity, if the user wants to select the data greater than 
0.4, this text does not support this kind of search, so we have to 
manually separated the text into two parts, namely operator and 
number. In addition to data quality, the missed links between 
different RDF resources is a serious issue. For instance, many 
data formats (SMILES, SDF, InChi and CID number) are 
available to present one chemical, but the machine does not know 
they actually talk the same subject. Thus we assigned the 
chemical a CID number (PubChem Compound ID) if available, as 
PubChem is a hub of the public compounds. Meanwhile, proteins 
can be presented as GI number, UNIPROT ID, EC number, PDB 
ID and gene symbol, so we added many separated RDF resource 
to connect them together. GI2UNIPROT offers the conversion 
between GI number and UNIPROT ID. All the proteins could be 
eventually converted to UNIPROT ID, that allows to link to 
pathways, protein-protein interaction and diseases. 
    Chem2Bio2RDF aims to bridge chemical and biological data, 
we linked our data to LODD and Bio2RDF using owl:sameAs. As 
LODD and BioRDF have strict namespace definition and 
dereferenceable URI. For instance, the URI of a drug in Bio2RDF 
is http://bio2rdf.org/drugbank_drugs: followed by drug id. This 
allows us simply link our data (i.e, drug, enzyme, protein, gene, 
pubmed) to them.  
3.2 Chem2Bio2RDF Faceted Browser 
MIT Simile project toolsets are used to provide user-friendly 
faceted RDF triple browser. Figure 3 shows the difference 
between normal SPARQL endpoint RDF browser and the 
Chem2Bio2RDF faceted RDF browser 
http://chem2bio2rdf.org/exhibit/drugbank.html). Currently it 
provides the following views:  
 Table view (see Figure 4a): The drug structure and related 
properties are displayed in a table format and the faceted 
filters on the right side can narrow down the view. For 
example, shown here are drugs that been approved by FDA 
in 2001 with the anti-allergic agent category; 
 Timeline view (See Figure 4b): It displays the timeline of 
drugs based on the year they get approved by FDA; 
 Tile view (see Figure 4c): It groups drugs first by year of 
approval, then by alphabetic order of drug names;  
 Thumbnail view (See Figure 4d): It displays drugs based on 
their drug names with drug structures as thumbnails. 
 
(a)  
 
(b) 
 
(c) 
 
(d) 
Figure 4. Screenshots of Chem2Bio2RDF Portal 
3.3 Automatic SPARQL generator 
If the users want to explore the relation between two classes, they 
do not necessarily need to know the specific dataset and the 
linkage between them, Link Path Generator (LPG) can 
automatically explores all possible link paths based on Systems 
Chemical Biology Data Source Ontology that models the 
semantic description of the datasets and their linkages. More 
specifically, LPG contains a graph mining module to enumerate 
all the possible routes from between two data sources within the 
linked graph, which can be translated into concrete SPARQL 
queries easily. LPG is written as: 
 
Where A and B are two classes which can be Chemical, 
Biological, Pathway and so on. m and n is the number of data 
sources relating to A and B respectively. The relation between A 
and B can be derived from the union of the paths between all the 
sources of A and all the sources of B. We implement a graph 
mining algorithm to enumerate all the unique, non-redundant (one 
that doesn’t revisit a node multiple times) paths between Ai and 
Bj.  For example, if we are looking for relation between Pathway 
and Side effect, 14 paths are generated by LPG as listed below: 
1) [sider -> kegg] contains 7 paths: 
[sider, compound_hub, bindingdb_ligand, bindingdb_protein, 
uniprot_hub, kegg] 
[sider, compound_hub, ctd, gene, gene2uniprot, uniprot_hub, kegg] 
[sider, compound_hub, drugbank_drug, drugbank_target, uniprot_hub, 
kegg] 
[sider, compound_hub, matador, uniprot_hub, kegg] 
[sider, compound_hub, pubchem_bioassay, gi, gi2uniprot, uniprot_hub, 
kegg] 
[sider, compound_hub, qsar, gene, gene2uniprot, uniprot_hub, kegg] 
[sider, compound_hub, ttd_drug, ttd_target, uniprot_hub, kegg] 
 
2) [sider -> reactome] contains 7 paths: 
[sider, compound_hub, bindingdb_ligand, bindingdb_protein, 
uniprot_hub, reactome] 
[sider, compound_hub, ctd, gene, gene2uniprot, uniprot_hub, reactome] 
[sider, compound_hub, drugbank_drug, drugbank_target,  uniprot_hub, 
reactome] 
[sider, compound_hub, matador, uniprot_hub, reactome] 
[sider, compound_hub, pubchem_bioassay, gi, gi2uniprot, uniprot_hub, 
reactome] 
[sider, compound_hub, qsar, gene, gene2uniprot, uniprot_hub, reactome] 
[sider, compound_hub, ttd_drug, ttd_target, uniprot_hub, reactome] 
Based on the link path, SPARQL can be constructed, and then all 
the results are combined to output. 
3.4 MEDLINE/PubMed Literature Cross-
validation 
MEDLINE/PubMed is the most frequently consulted online 
scientific medical resource in the world. In our Chem2Bio2RDF 
portal, we are processing 17,862,546 scientific abstracts from 
1966 to present to rdf format. Not only the normal citation 
information, i.e. authors, journal, publication date, etc. have been 
processed, but also the Chem/Bio information have also been 
extracted. Current, our extractions are based on extact dictionary 
match. We used the PubChem as the dictionary to identify the 
compounds. The Uniprot human genes are used as the dictionary 
for the genes. The MESH disease terms and the COSTART side 
effects are applied to diseases and side effects extraction. As 
shown in Figure 5, the chemical compounds, genes, diseases and 
side effects for each abstracts are extracted and then associated 
with other data sources. 
 
Figure 5, Chem/Bio Extraction for MEDLINE/Pubmed 
    After the Chem/Bio terms extraction, each literature is 
connected to other notes (chemical, genomic, phenotype, etc.) in 
the Chem2Bio2RDF graph, which provides a more meaningful 
way to search and classify the literature based on domain 
knowledge. For instance, if users want to study the literatures 
resource for a given drug, they can retrieve the literatures that 
contain either the given drug or the compound with a similarity 
value greater than a given threshold. If users are interested in 
studying certain disease, both the literatures contain the given 
disease and the literatures contain the compounds/genes that 
associated with the given disease can be retrieved. Those potential 
search methods enable a broad way to retrieve documents based 
on domain knowledge.  
    Meanwhile, the Chem/Bio information extraction for 
MEDLINE/PubMed provides a cross-validation for our 
Chem2Bio2RDF search result. As shown in Figure 6, the left 
window allows users to specify two search terms, for example, 
find the relationships for the compound, doxazosin, and the side 
effect, necrosis. The right window shows the network 
visualization based on our RDF data, which connect the 
compound with its targets, targets with pathways, and then 
associated the pathways with side effects. More details about this 
network validation are shown in case 2.  The bottom window 
provides the MEDLINE/PubMed results for this given input by 
retrieving the literatures that contain both inputs and the 
associated genes/pathways. This MEDLINE/PubMed validation 
can also used to rank the generated paths based on literature 
confidence.  
  
Figure 6. MEDLINE/PubMed cross-validation service 
3.5 Cytoscape Plugin 
Cytoscape is an open source bioinformatics tool originally 
developed for visualizing and analyzing biological networks. 
Over the past few years, Cytoscape has been used for the analysis 
of chemgenomics data which explores the relationships between 
compounds, genes and diseases. Since Cytoscape allows users to 
develop plugins that are best suited to the needs of their own 
dataset, we developed a plugin called Chem2Bio2RDFViz that 
allows users to interact with the Chem2Bio2RDF dataset in the 
most efficient manner possible (see Figure 8). 
 
Figure 8. Cytoscape plugin prototype 
Chem2Bio2RDFViz allows you to enter the names of the 
drug/protein/side effect/pathway/disease/gene whose network you 
would like to visualize and analyze. Once you enter the text, a 
network will be generated in the Cytoscape desktop which can be 
further manipulated according to the user’s needs. Right clicking 
on each node leads to a range of choices that give you more 
information related to the network. The figure below shows the 
visualization of the network Doxazosin and its side effect 
Necrosis. Right clicking on the node Doxazosin will give you the 
MEDLINE/PubMed option that displays the MEDLINE/PubMed 
articles related to Doxazosin and Necrosis.Also, we can use the 
myriad inbuilt features of Cytoscape to understand the networks 
better. 
 
4. Use cases 
Here we provide three use cases to demonstrate the different 
levels of drug discovery. 
4.1 Compound targets exploration 
Given a drug, its targets are needed to be explored to understand 
its real mechanism, while for a drug-like compound, finding all its 
possible targets in the early discovery stage is desired in order to 
avoid the unexpected side effects in the clinical experiments. It’s 
possible that many efforts have been made to identify the targets 
of a drug, but the results are scattered in the literature or hidden in 
some experimental records. This raises the following question:  
Question: Given a drug (or chemical), find its possible targets 
(i.e., Gefitinib). 
SPARQL:  
SELECT ?uniprot  WHERE {  
      {?compound compound:CID ?compound_cid . FILTER 
(?compound_cid= 123631) . 
      ?chemical bindingdb_ligand:cid ?compound . 
       ?target bindingdb_interaction:monomerid ?chemical. 
      ?target bindingdb_interaction:uniprot?uniprot. 
      ?target bindingdb_interaction:ic50_value ?ic50  . FILTER 
(?ic50<10000) .   } 
UNION  {?compound compound:CID ?compound_cid . FILTER 
(?compound_cid= 123631) . 
      ?drug drugbank_drug:CID ?compound . 
      ?drugtarget drugbank_interaction:DBID ?drug. 
      ?drugtarget drugbank_interaction:human ?human .  FILTER 
(?human="1") . 
      ?drugtarget drugbank_interaction:SwissProt_ID ?uniprot.      }} 
GROUP BY ?uniprot 
    Gefitinib (CID=123631) is widely investigated in non-small 
cancer of the lung, colon cancer, breast cancer and cancer of the 
head and neck. We are only using DrugBank and BindingDB 
dataset to find its targets in this example. DrugBank offers 
approved drug targets from literature. As it considers non-human 
target, we used a filter to select only human targets. BindingDB 
provides drug target experimental interaction results. IC50 is a 
measurement of binding affinity, we selected ic50<10000nm (nm 
is the default unit) to guarantee the compound is able to interact 
the target.  
    While using only DrugBank, it yields one result P00533 
(EGFR: Epidermal growth factor receptor), whose well known 
inhibitor is Gefitinib. While adding another dataset BindingDB, 
We got a new possible target P04626 (ERBB2: Receptor tyrosine-
protein kinase erbB-2). EGFR (the known Gefitinib target) is part 
of the ERBB receptor family, which has four closely related 
members: EGFR (ERBB1), HER2 (ERBB2), HER3 (ERBB3) and 
HER4 (ERBB4), thus Gefitinib is active against ERBB2 is not 
surprising, however, DrugBank does not have this information, 
thus it’s necessary to consider all the datasets as much as possible. 
4.2 Disease specific chemical discovery 
Drug discovery process generally starts with the disease target 
identification, followed by hits selection (active compounds 
against the disease target). Finding the potential chemicals is the 
main task in the early drug discovery stage. As so many public 
data emerges, it becomes possible to find some intriguing 
chemicals by running one SPARQL. This is particularly of 
interest to some lower-profitable disease like malaria that is paid 
little attention by pharmaceutical companies. But academia and 
the small companies do not have adequate funding to screen 
millions of compounds in order to find the hits. Chem2Bio2RDF 
attempts to collect all this kind of public data and the compounds 
can be easily obtained by the following SPARQL.  
 
Questions: Find a disease (i.e., Malaria) specific chemicals  
SPARQL: 
SELECT * WHERE {  
 ?chemogenomics chemogenomics:CID ?compound_cid .  
 ?chemogenomics chemogenomics:GENE ?gene_symbol .   
 ?omim omim:gene ?gene_symbol .   
 ?omim omim:Disorder_name  ?disease . FILTER 
regex(?disease,"Malaria","i") .   
} 
 
The SPARQL starts to find disease causing genes in OMIM and 
then select the associated compounds of the genes. 1,003 
compounds and 5 disease causing genes are returned from this 
query, which enable scientists to do further experiments. 
4.3 Adverse drug reaction  
Adverse reaction in drug usage, as the notion self-suggests, has 
serious consequence and is often subject to rigorous investigation 
in pharmaceutical R&D processes. In this case, we integrate into 
Chem2Bio2RDF another scenario to study the most significant 
pathways that are associated with a given drug affect. The 
association between side effect and pathway is made possible 
using pathway’s gene components that are targets of related 
drugs. More specifically, we consider a gene is related to a certain 
side effect if at least two drugs targeting this gene incur the side 
effect. On top of that, if there exists a pathway that contains more 
than 2 gene targets that associated with that side effect, an 
associative relationship between the pathway and side effect can 
be drawn. Clearly, the more these associative paths can be 
discovered, the stronger the evidence of such pathway-adverse 
drug effect association it becomes.  
 
Question: Find the top 5 pathways in the KEGG pathway contain 
at least two of the efficient target that associated with a given side 
effect (i.e. hepatomegaly). A gene target is consider as efficient if 
the gene is targeted by at least two drugs that cause the given side 
effect. 
SPARQL: 
SELECT ?pathway_id (count(?pathway_id) as ?count) WHERE {  
 ?sider2compound sider:side_effect ?side_effect .  FILTER 
regex(?side_effect,"hepatomegaly","i") .  
 ?sider2compound sider:cid ?compound .  
 
 ?drug drugbank_drug:CID ?compound .   
 ?drug2target drugbank_interaction:DBID ?drug .   
 ?drug2target drugbank_interaction:SwissProt_ID ?uniprot .   
 ?kegg_pathway kegg_pathway_protein:Uniprot ?uniprot .   
 ?kegg_pathway kegg_pathway_protein:PathwayID ?pathway_id .   
 } GROUP BY ?pathway_id ORDER BY ?count  
 
In this SPARQL, we need to first map side effect to drugs, and 
then map drug to targets. At the end, the target will be mapped to 
pathway. All the possible connections between side effect and 
pathway are counted to get the most reasonable pathways that 
associated with the given side effect. 
Results: Available studies suggest that hepatic toxicity has been 
the most frequent single cause of safety-related drug withdrawal 
(e.g.,ticrynafen, benoxaprofen, bromfenac, troglitazone, 
nefazodone). Hepatotoxicity discovered after approval from 
marketing also has limited clinical use of many drugs, including 
isoniazid, labetalol, trovafloxacin, tolcapone, and felbarmate. 
Thus, it is important to systematically review the compounds, 
gene target and pathways that associated with liver injury.  
    In our mapping process, we use the hepatic necrosis, hepatitis 
and hepatomegaly as an example to study the relationship 
between drugs, targets, pathways and side effect. The graph is 
shown as following: 
 
 
Figure 9: Adverse Drug Reaction 
 
Figure 9 shows the top 5 pathways that associated with the three 
majority liver injury. It demonstrates that the mechanisms for 
hepatic necrosis and hepatitis are very close. They share the top 5 
pathways: Arachidonic acid metabolism, VEGF signaling 
pathway, Neuroactive ligand-receptor interaction, small cell lung 
cancer, and pathways in cancer. The mechanism for 
hepatomegaly is a little bit different. The top 5 pathways of 
hepatomegaly contain the calcium signaling and gap junction 
pathway, which are not involved in the hepatic necrosis and 
hepatitis. Literature review [14] shows that those pathways are 
highly correlated with liver injury. For instance, the increase 
concentration of calcium in the calcium signaling pathway will 
cause the damage of hepatic cell. The targets we discovered are 
also known as the major targets for liver diseases based on 
literature reviews [11]. 
 
5. Evaluation 
We evaluate the outcomes from the previous case studies against 
the confirmed evidence in literature search as well as salient 
domain knowledge. In addition, we also developed 
comprehensive assessment to examine the coverage of datasets in 
their associated domains. Finally we illustrate the improvement 
gained through Chem2Bio2RDF as opposed to our previous work 
where no semantic web framework is deployed. 
5.1 Study of systems chemical biology 
The difficulties of polypharmacology are to explore the 
combination of targets and then to identify active compounds 
against the sets of targets.  Linking between chemical, biological, 
systems, and phenotype data is demonstrated to be a promising 
way to address the problems. For example, linking between 
bioassay data and market drug data enables to explore the 
compounds similar to the drug that already shows 
polypharmacology. Quinacrine, which has been used as an 
anthelmintic and in the treatment of giardiasis and malignant 
effusions, shows polypharmacology. One compound loxapine 
(CID 71399) is found to show similar polypharmacology with 
quinacrine. Loxapine is active in both BioAssay 859 and 
BioAssay 377, whose targets are CHRM1 and ABCB1 
respectively. As loxapine tends to be hydrophobic molecules, 
medicinal chemists would not be surprised that it is active in 
BioAssay 377 which identifies substrates (or inhibitors) for 
multidrug resistance transporter. It is also reported that loxapine 
might get metabolized to amoxapine that is a considerably weak 
antagonist in BioAssay 859 [9].  Other than loxapine, many 
identified compounds such as oxybutynin and dexamethasone 
were proved to show polypharmacology by literature reviews. 
    While we link bioassay data to pathways, we could identify the 
compounds that inhibit at least two of proteins in a pathway, 
leading to the pathway dysfunction. For example, compound CID 
6,419,769 could interact with proteins HSD11B1 and AKR1C4, 
which are in the different branches of C21-Steroid hormone 
metabolism pathways. The blocking of the pathway might be able 
to partially explain why CID 6,419,769 has side effect [1]. In 
protein-protein interaction network, two proteins are connected if 
both are physically interacted. In terms of polypharmacology, the 
deletion of one protein does not affect the whole network, but if 
two connected nodes with high degree were deleted, the network 
would be disturbed. For example, by linking bioassay to PPI, we 
found that two compound (CID 460,747 and CID 9,549,688) are 
active against two high degree proteins (PLK1 and TP53) which 
are associated with cancer. Via linking data sources among 
different domains, not only promising compounds to be high 
effective could be identified but also the risk of compounds could 
be somehow evaluated.  
5.2 Dataset and result coverage 
There are parallel contributions from different data sources and 
vendors toward same domain (for example, KEGG and Reactome 
are two independent data vendor provides same datum coverage 
over pathway domain), therefore the approach in which one single 
data source is made delegating the entire domain could produce 
incomplete outcome. To avoid this potential pitfall, for each 
domain in Chem2Bio2RDF, we have collected from a variety of 
data sources to make the ensemble as complete as possible. In 
particular, coverage for systems and chemogenomics is under 
close scrutiny due to their central roles in system chemical 
biology. Here we list the percentage coverage for PPI, pathway 
and chemogenomics and demonstrate the significance of 
integration using semantic web. 
    In PPI (Table 1), HPRD and DIP have 35,645 and 32,976 
unique protein pairs respectively, and the total number of unique 
pairs in two datasets is 67,769. Each dataset contributes almost 
half of the pairs, and both share very little number of common 
pairs. The PPI network would not be complete if either dataset 
were ignored. Pathway is more complicated than PPI, since each 
organization could have its own definition of pathway, which 
makes the whole integration very difficult. For example, the 
pathway in Reactome is usually composed by a small number of 
proteins, although the total number of pathways is more than 
KEGG, the proteins involved in Reactome are far less than KEGG 
(Table 2). We are not able to judge which one is better, thus we 
have to consider all pathway datasets together. Figure 10 shows 
the dataset distribution of chemogenomics data.  A chemical 
protein (gene) interaction is recorded as one entry, and all the 
unique interactions were derived from 10 datasets. We did not 
consider another two chemogenomics data sets (KEGG Ligand 
and PharmGKB), as KEGG Ligand includes only metabolic 
molecules rather than chemicals designed for drug discovery and 
many drugs in PharmGKB only provide names from which the 
chemical identifier is not able to be linked to compound.  Many 
datasets only contribute a small portion of interactions so that it is 
not able to represent all chemogenomics data. Some of the 
datasets are quite small but they cannot be ignored.  For example, 
BindingMOAD provides the protein and ligand complex crystal 
information which is the most accurate binding data. Kidb (called 
PDSP) is only interested in the receptors rather than all the protein 
spaces. DrugBank provides the most comprehensive drug and its 
target interactions. 
 
Table 1: PPI data source distribution 
Data source # of records percentage 
HPRD 35645 52.6% 
DIP 32976 48.7% 
ALL 67769  
 
Table 2: Pathway data source distribution 
Data source protein pathway 
# of records percentage # of 
records 
percentage 
KEGG 8172 81.0% 192 34.8% 
Reactome 4397 43.6% 360 65.2% 
ALL 10091  552  
 
 
Figure 10: chemogenomics data source distribution 
 
One dataset hardly be able to cover all the records of one domain, 
thus missing some of the datasets might neglect many link paths, 
sometimes, the results might even be changed significantly. We 
designed the following experiments to answer to the case 1 
question, where we are searching for disease specific chemicals. 
In this task, we need to first identify disease genes (OMIM and 
PharmGKB) and then find chemicals interacting with the gene or 
gene expression products (BindingDB, DrugBank, ChEMBL and 
PubChem BioAssay). In our evaluation, we either selected one 
dataset in each step or selected all the datasets. As the table 4 
shows, the number of chemicals retrieved from all datasets is far 
more than that only one dataset is considered. 
 
Table 4: Results of discovering disease specific chemicals 
Dataset used # of chemical discovered 
OMIM, DrugBank 77 
OMIM, BindingDB 175 
OMIM, PubChem 3577 
OMIM, ChEMBL 2036 
PharmGKB,DrugBank 292 
PharmGKB, BindingDB 1256 
PharmGKB, PubChem 28410 
PharmGKB, ChEMBL 20513 
ALL 45606 
5.3 Comparison with previous work 
In the previous study, only 4 datasets (PubChem, DrugBank, 
KEGG and HPRD) were studied [5], no attempt is made to 
integrate multiple datasets within one domain simultaneously. In 
Chem2Bio2RDF, efforts have been made to provide coverage 
over the comprehensive landscape of system chemical biology, 23 
datasets so far has been integrated, as a direct result; the expected 
entity pairs discovered has increased significantly. Moreover, 
LPG would answer user’s queries by automatically locating 
related datasets. 
    In addition, the performance has been improved as well as lots 
of time was required to parse the heterogeneous datasets 
previously.  But now, since data sources have been published as 
RDF triples, SPARQL queries can be used to directly identify 
hidden knowledge.    
    In the work of adverse drug reaction study[22], it relies on the 
internal data source which includes 1,458,680 unique 
compounds and 2,190 unique targets, Chem2Bio2RDF 
currently covers 235,313 compounds, 19,534 genes, 641, 855 
chemogenomics which are public accessible. However, we must 
take care of the quality of data in public domain. We also need to 
build robust chemogenomics predictive model based on the rich 
chemogenomics data source, as it is impossible that every 
compound is tested against all the targets. 
 
6. Conclusion and Future work 
This paper discusses our on-going effort to create an user-friendly 
Linked Open Data portal for chemical biology. It applies semantic 
web technologies to integrate data and identify hidden 
association. Comparing with other LOD portals, currently 
Chem2Bio2RDF portal contains the following features: a RDF 
faceted browser, an automatic SPARQL query generator, a 
MEDLINE/PubMed literature cross-validation service, a 
cytoscape pulgin, and a WENDI 2.0 service for disease-drug-
compound discovery.  
    Our future work will focus on: (1) extending cytoscape 
visualization plugin to enable analytical graph mining and 
association detection; (2) adding a predictive model for compound 
gene associations, as not every compound is tested against all the 
targets, a predictive model is necessary; (3) applying 
CRF(common random field) name entitiy method to identify the 
chem./bio terms to provide an extentable gene, compound, 
pathway, disease and drug extraction for MEDLINE/PubMed 
literatures; (4) enriching provenance data to the current 
Chem2Bio2RDF data to enable provenance-based filtering and 
visualization; and (5) identifying semantic associations among 
different types of entities to enable complex drug discovery.  
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